Effects of CGRP receptor antagonism in nitroglycerin-induced hyperalgesia

R. Greco, A. S. Mangione, F. Siani, F. Blandini, M. Vairetti, G. Nappi, G. Sandrini, M. G. Buzzi, C. Tassorelli

Research output: Contribution to journalArticlepeer-review


Background: The release of calcitonin gene-related peptide (CGRP) from trigeminal nerves plays a central role in the pathophysiology of migraine and clinical evidence shows an antimigraine effect for CGRP receptor antagonists. Systemic administration of nitroglycerin (NTG), a nitrovasodilator, consistently provokes spontaneous-like migraine attacks in migraine sufferers; in the rat, systemic NTG induces a condition of hyperalgesia, probably through the activation of cerebral/spinal structures involved in nociceptive transmission. Aim: The aim of this article is to test the analgesic effect of the CGRP receptor antagonist MK-8825 in two animal models of pain that may be relevant for migraine: the tail flick test and the formalin test performed during NTG-induced hyperalgesia. Results: MK-8825 showed analgesic activity when administered alone at both the tail flick test and the formalin test. Furthermore, the CGRP antagonist proved effective in counteracting NTG-induced hyperalgesia in both tests. MK-8825 indeed reduced the nociceptive behavior when administered either simultaneously or prior to (30-60 minutes before) NTG. Conclusion: These data suggest that MK-8825 may represent a potential therapeutic tool for the treatment of migraine.

Original languageEnglish
Pages (from-to)616-623
Number of pages8
Issue number8
Publication statusPublished - 2014


  • CGRP receptor antagonist
  • hyperalgesia
  • migraine
  • Nitroglycerin

ASJC Scopus subject areas

  • Clinical Neurology


Dive into the research topics of 'Effects of CGRP receptor antagonism in nitroglycerin-induced hyperalgesia'. Together they form a unique fingerprint.

Cite this